Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

Key facts

Study ID: NCT04057898
Run by: MediciNova
People needed: 234
Starts: 2020-05-28
Expected to finish: 2028-04-01
Last updated by the study team: 2026-03-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

University of California — Orange, California, United States
Mayo Clinic — Jacksonville, Florida, United States
Augusta University — Augusta, Georgia, United States
Indiana University IU Health Neuroscience Center — Indianapolis, Indiana, United States
Johns Hopkins University — Baltimore, Maryland, United States
Hennepin Healthcare Research Institute — Minneapolis, Minnesota, United States
SUNY Upstate Medical University — Syracuse, New York, United States
Duke University — Durham, North Carolina, United States
Lehigh Valley Health Network — Allentown, Pennsylvania, United States
University of Virginia Health System — Charlottesville, Virginia, United States
University of Alberta Hospital — Edmonton, Alberta, Canada
McMaster University Medical Center — Hamilton, Ontario, Canada
Sunnybrook Research Institute — Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital — Montreal, Quebec, Canada
University of Saskatchewan - Sastakoon Hospital — Saskatoon, Saskatchwean, Canada
Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval — Québec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.